ATE360019T1 - Substituierte 1,3-oxathiolane mit antviralen eigenschaften - Google Patents

Substituierte 1,3-oxathiolane mit antviralen eigenschaften

Info

Publication number
ATE360019T1
ATE360019T1 AT04018075T AT04018075T ATE360019T1 AT E360019 T1 ATE360019 T1 AT E360019T1 AT 04018075 T AT04018075 T AT 04018075T AT 04018075 T AT04018075 T AT 04018075T AT E360019 T1 ATE360019 T1 AT E360019T1
Authority
AT
Austria
Prior art keywords
oxathiolanes
substituted
antviral
properties
relates
Prior art date
Application number
AT04018075T
Other languages
English (en)
Inventor
Tarek S Mansour
Jin Haolun
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of ATE360019T1 publication Critical patent/ATE360019T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04018075T 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antviralen eigenschaften ATE360019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/230,317 US5587480A (en) 1990-11-13 1994-04-20 Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
ATE360019T1 true ATE360019T1 (de) 2007-05-15

Family

ID=22864746

Family Applications (3)

Application Number Title Priority Date Filing Date
AT95915098T ATE214066T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
AT04018075T ATE360019T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antviralen eigenschaften
AT01118810T ATE275144T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95915098T ATE214066T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01118810T ATE275144T1 (de) 1994-04-20 1995-04-19 Substituierte 1,3-oxathiolane mit antiviralen eigenschaften

Country Status (12)

Country Link
US (1) US5587480A (de)
EP (3) EP1473294B1 (de)
JP (1) JPH09512526A (de)
AT (3) ATE214066T1 (de)
AU (1) AU693884B2 (de)
CA (1) CA2188283C (de)
DE (3) DE69535476T2 (de)
DK (3) DK1473294T3 (de)
ES (3) ES2286542T3 (de)
HK (1) HK1041487B (de)
PT (3) PT1473294E (de)
WO (1) WO1995029176A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
DK0831852T3 (da) * 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP1104415B1 (de) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Verfahren zur herstellung von 1,3-oxathiolannukleoside
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
KR100517163B1 (ko) 2000-02-10 2005-09-26 미쯔이카가쿠 가부시기가이샤 1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
BRPI0210444B1 (pt) * 2001-06-15 2017-06-20 Shire Canada Inc. Stereo-relevant process for the preparation of nucleosidal analogs
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
US7968703B2 (en) 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
ES2446102T3 (es) * 2005-03-14 2014-03-06 Shire Canada Inc. Proceso y procedimientos para la preparación de cis-2-hidroximetil-4-(citosin-1-il)-1,3-oxatiolano ópticamente activo o sales farmacéuticamente aceptables del mismo
RU2430919C2 (ru) * 2005-03-14 2011-10-10 Шайр Канада Инк. Способы получения оптически активного цис-2-гидроксиметил-4-(цитозин-1'-ил)-1,3-оксатиолана или его фармацевтически приемлемых солей
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20080249066A1 (en) * 2007-03-23 2008-10-09 Ardea Biosciences, Inc. Antiviral compounds and compositions
NZ584193A (en) * 2007-09-28 2011-07-29 Avexa Ltd A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
PT2346890E (pt) * 2008-09-05 2013-06-27 Shire Canada Inc Resolução enantiomérica de nucleósidos de 1,3-oxatiolano 2,4-dissubstituídos
US8153416B2 (en) 2008-12-10 2012-04-10 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution
WO2010099518A2 (en) 2009-02-27 2010-09-02 Thesis Chemistry, Llc Method for manufacture of 2-oxoimidazolidines
TW201131192A (en) * 2010-03-01 2011-09-16 Univ Nat Central A co-crystal compound of optical devices
CA2854946A1 (en) * 2011-11-18 2013-05-23 Avexa Limited Apricitabine and pi combination therapy
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法
WO2024016639A1 (zh) * 2022-07-21 2024-01-25 华创合成制药股份有限公司 一种抗病毒感染的化合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE3529263A1 (de) * 1985-08-16 1987-02-19 Hoechst Ag Verfahren zur herstellung von 2-oxo-1,3-dioxolanen
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
JP2960164B2 (ja) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換１，３−オキサチオラン類および置換１，３−ジチオラン類
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
ES2228714T3 (es) 2005-04-16
ATE214066T1 (de) 2002-03-15
WO1995029176A1 (en) 1995-11-02
DK1224940T3 (da) 2004-12-27
EP0756595B1 (de) 2002-03-06
EP1153924B1 (de) 2004-09-01
DE69535476T2 (de) 2008-01-03
AU2211895A (en) 1995-11-16
DK1224940T4 (da) 2010-10-25
ES2172580T3 (es) 2002-10-01
AU693884B2 (en) 1998-07-09
HK1041487A1 (en) 2002-07-12
HK1005544A1 (en) 1999-01-15
HK1041487B (en) 2005-01-07
EP1473294B1 (de) 2007-04-18
ES2286542T3 (es) 2007-12-01
DE69525742D1 (de) 2002-04-11
EP1473294A2 (de) 2004-11-03
EP1473294A3 (de) 2004-11-17
PT756595E (pt) 2002-08-30
JPH09512526A (ja) 1997-12-16
DK1473294T3 (da) 2007-09-17
PT1473294E (pt) 2007-06-11
DE69533458D1 (de) 2004-10-07
DK0756595T3 (da) 2002-06-17
CA2188283A1 (en) 1995-11-02
ATE275144T1 (de) 2004-09-15
CA2188283C (en) 2003-11-04
HK1073460A1 (en) 2005-10-07
EP1153924A2 (de) 2001-11-14
EP1153924A3 (de) 2001-11-21
DE69525742T2 (de) 2002-09-26
DE69535476D1 (de) 2007-05-31
DE69533458T2 (de) 2005-10-27
EP0756595A1 (de) 1997-02-05
US5587480A (en) 1996-12-24
PT1153924E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
ATE214066T1 (de) Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
SE9604786D0 (sv) New compounds
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
DE69131311D1 (de) Fibrinogen-Rezeptor-Antagonisten
NO178189C (no) Tetrazolmellomprodukter
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
PH25859A (en) Composition for treatment of ischemic disorder
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
PT992509E (pt) Novos derivados macrolidos
GR3036532T3 (en) Use of lactam compounds as pharmaceutical agents
ES2102772T3 (es) Compuesto citotoxico y antiviral.
ATE58135T1 (de) 1,3-oxathianderivate.
NZ229300A (en) Substituted-2-ethenyl-3,4,5,6-tetrahydrothieno (4,3,2-cf)(3)benzazepine derivatives and pharmaceutical compositions
EP0802179A4 (de) Derivate substituierter amidinonaphthylester
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
ES2081192T3 (es) Inhibidor de timidina quinasa viral del herpes simple.
FI905922A0 (fi) Antagonister foer a-adrenerga receptorer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1473294

Country of ref document: EP

EEFA Change of the company name